

*Tru*

A circular stamp with the text "OIPE IAP35" at the top, "JUL 24 2006" in the center, and "PATENT &amp; TRADEMARK OFFICE" at the bottom.

Art Unit: **1616**

Examiner: **Unassigned**

### For: Estrogenic Compounds as Anti-Mitotic Agents

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed, with the exception that copies of U.S. patents are not being provided, pursuant to the waiver of 37 C.F.R. for patent applications filed after June 30, 2003.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

**KILPATRICK STOCKTON LLP**  
1100 Peachtree Street, Suite 2800  
Atlanta, Georgia 30309  
(404) 815-6500  
Our Docket: 05213-3001 (43170-295490)

Shirley E. Brosmore  
Reg. No. 56,167

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20<sup>th</sup> day of July, 2006.

Shirley E. Brosmore  
Shirley E. Brosmore – Reg. No: 56,

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known		
				Application No.	10/789,471	
				Filing Date	2/27/2004	
				First Named Inventor	D'Amato	
				Group Art Unit	1616	
				Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number		05213-3001 (43170-295490)


**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	1	<b>Author:</b> ARNOLDI et al. <b>Title:</b> Sweet Isovanillyl Derivatives: Synthesis and Structure-Taste Relationships of Conformationally Restricted Analogs (Abstract only)  <b>Publ:</b> <u>Journal of Agric. Food Chem.</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 46(10)      <b>Pages:</b> 4002-4010      <b>Date:</b> 1998         </div>	
	2	<b>Author:</b> BHATTACHARYYA et al. <b>Title:</b> Tubulin aggregation and disaggregation: Mediation by two distinct vinblastine-binding sites  <b>Publ:</b> <u>National Academy of Sciences</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 73 (7)      <b>Pages:</b> 2375 - 2378      <b>Date:</b> 07/1976         </div>	
	3	<b>Author:</b> GOOD, D.J. et al. <b>Title:</b> A Tumor Suppressor-dependent Inhibitor of Angiogenesis is Immunologically and Functionally Indistinguishable from a Fragment of Thrombospondin  <b>Publ:</b> <u>Proceedings of the National Academy of Science USA</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 87      <b>Pages:</b> 6624-6628      <b>Date:</b> 09/90         </div>	
	4	<b>Author:</b> HIMES et al. <b>Title:</b> Action of the Vinca Alkaloids Vincristine, Vinblastine, and Desacetyl Vinblastine Amide on Microtubules in Vitro  <b>Publ:</b> <u>Cancer Research</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 36      <b>Pages:</b> 3798-3802      <b>Date:</b> 10/1976         </div>	
	5	<b>Author:</b> HOLDEN et al. <b>Title:</b> Mitotic Arrest by Benzimidazole Analogs in Human Lymphocyte Cultures  <b>Publ:</b> <u>Environmental Mutagenesis</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 2      <b>Pages:</b> 67-73      <b>Date:</b> 1980         </div>	
	6	<b>Author:</b> MANFREDI et al. <b>Title:</b> Taxol: An Antimitotic Agent with a New Mechanism of Action  <b>Publ:</b> <u>Pharmacology &amp; Therapeutics</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 25 (1)      <b>Pages:</b> 83-125      <b>Date:</b> 1984         </div>	
	7	<b>Author:</b> MARO et al. <b>Title:</b> Changes in Actin Distribution During Fertilization of the Mouse Egg  <b>Publ:</b> <u>Journal of Embryology and Experimental Morphology</u>  <div style="text-align: right;"> <b>Vol/Iss:</b> 81      <b>Pages:</b> 211-237      <b>Date:</b> 1984         </div>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Application No.		10/789,471
				Filing Date		2/27/2004
				First Named Inventor		D'Amato
				Group Art Unit		1616
				Examiner Name		Unassigned
Sheet	2	of	2	Attorney Docket Number		05213-3001 (43170-295490)

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	8	Author: SCHIFF et al. Title: Tubulin: A Target for Chemotherapeutic Agents  Publ: Molecular Actions and Targets for Cancer Chemotherapeutic Agents  Vol/Iss: Pages: 483-507 Date: 01/01/1981	
	9	Author: YANG, Ning-Sun Title: Gene Transfer into Mammalian Somatic Cells <i>A Vivo</i>  Publ: Critical Reviews in Biotechnology  Vol/Iss: 12 (4) Pages: 335-356 Date: 1992	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

**D'AMATO ET AL.**Serial No. **10/789,471**Filed: **FEBRUARY 27, 2004**For: **ESTROGENIC COMPOUNDS AS ANTI-MITOTIC  
AGENTS**

Art Unit: Unassigned

**APPENDIX A**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request that the Examiner review the below-listed patent applications. Please review and initial each listed application and return a copy of the initialed Supplemental Appendix A to the Applicants. For convenience, copies of non-published applications are included.

The serial numbers and/or publication numbers of the below-listed U.S. patent applications are listed on this form as provided in MPEP §609(D), rather than a PTO-1449 form, to avoid the serial numbers of the pending U.S. patent applications being published on any patent that may issue from this application. **Applicants do not waive the confidential nature of any of the below-listed patent applications.**


---

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20<sup>th</sup> day of July, 2006.

  
Shirley E. Brosmore - Reg. No. 56,167

- \_\_\_\_\_ 1. U.S. Published Application US 2005/0020555 published 1/27/2005
- \_\_\_\_\_ 2. U.S. Published Application US 2006/0079576 published 4/13/2006

Respectfully Submitted,

By:   
Shirley E. Brosmore  
Reg. No. 56,167

KILPATRICK STOCKTON LLP  
1100 Peachtree Road  
Suite 2800  
Atlanta, Georgia 30309/4530  
(404) 815-6500  
Our Docket: 052130-3001 (43170-295490)